Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
ImmunosuppressionStem Cell TransplantBone Marrow Transplant
Interventions
DRUG

Tacrolimus

Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.

DRUG

Tacrolimus

Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT04041219 - Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients | Biotech Hunter | Biotech Hunter